Citi raised the firm’s price target on Cogent Biosciences (COGT) to $22 from $15 and keeps a Buy rating on the shares. The firm says that following the results for bezuclastinib in non-advanced systemic mastocytosis, the drug is being viewed as upgrade over Blueprint Medicines’ (BPMC) Ayvakit. Citi sees more data catalysts for Cogent.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences: Buy Rating Affirmed Amid Promising Trials and Strategic Advantages
- Cogent Biosciences Raises $230M Through Stock Sale
- Cogent Biosciences 22.2M share Spot Secondary priced at $9.00
- Cogent Biosciences $150M Spot Secondary; price range $9.00-$9.50
- Cogent Biosciences offers to sell $150M in common stock